# EDGAR Filing Document

**Accession Number:** 0001479615
**File Stem:** 0001193125-25-319156
**Filing Date:** 2025-12
**Character Count:** 14123
**Document Hash:** fc084cc0ba116e8bd5113b91d388221d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-319156.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001193125-25-319156

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20251214

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silence Therapeutics plc
- **CENTRAL INDEX KEY:** 0001479615
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39487
- **FILM NUMBER:** 251571498

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP
- **BUSINESS PHONE:** 44-0-20-3457 6900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HAMMERSMITH GROVE
- **STREET 2:** OFFICE 205
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W6 7AP

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** December 14, 2025

------

Silence Therapeutics plc

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| England and Wales | 001-39487 | Not Applicable |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 12 Hammersmith Grove <br>London<br>United Kingdom |  | W6 7AP |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: +**44 20 3457 6900

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share  | SLN | The Nasdaq Stock Market LLC<br>|
| Ordinary share, nominal value £0.05 per share\* | \* | The Nasdaq Stock Market LLC |

---

\* *Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 15, 2025, Silence Therapeutics plc (the "Company") announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and a member of the Company's Board of Directors (the "Board") since 2022, agreed by mutual consent to end his employment with the Company and step down from the Board effective December 14, 2025 (the "Effective Date").

The Company and Mr. Tooman intend to enter into a separation agreement (the "Separation Agreement"), which will provide for the terms of Mr. Tooman's separation from employment. The Company will file an amendment to this Current Report on Form 8-K to update this disclosure after the terms of the Separation Agreement are finalised.

*Appointment of Principal Executive Officer*

On the Effective Date, Iain Ross, Chairman of the Company's Board, was appointed as interim principal executive officer of the Company, effective immediately. The biography for Mr. Ross is contained in the Company's definitive proxy statement, filed with the U.S. Securities and Exchange Commission on May 16, 2025. The terms of Mr. Ross' additional compensation for service as principal executive officer, in addition to his current role as Chairman of the Board, have yet to be determined. The Company will file an amendment to this Current Report on Form 8-K when such compensation has been determined.

*Appointment of Director*

On the Effective Date, upon the recommendation of the Nominations Committee, the Board appointed James Ede-Golightly to serve as a director of the Company, effective immediately. In accordance with the Company's articles of association, Mr. Ede-Golightly will serve for an initial term expiring at the end of the Company's 2026 annual general meeting and expects to stand for re-appointment at the 2026 annual general meeting. Mr. Ede-Golightly has not been appointed to a committee of the Board at this time.

Mr. Ede-Golightly, age 46, previously served a member of the Board from April 2019 to June 26, 2025. He currently serves as Chairman of Oxehealth Ltd, EBP Holdings Ltd and ORA Global Ltd. Among other directorships, Mr. Ede-Golightly is also Non-Executive Director of Gulfsands Petroleum Plc and C4X Discovery Holdings Ltd. Mr. Ede-Golightly was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. Mr. Ede-Golightly is a CFA Charterholder and holds an M.A. degree in economics from Cambridge University.

The terms of Mr. Ede-Golightly' compensation for service as a director have yet to be determined. The Company will file an amendment to this Current Report on Form 8-K after the terms of the compensation have been finalised.

The Company also intends to enter into a standard form of deed of indemnity with Mr. Ede-Golightly in connection with his appointment to the Board, the form of which was previously filed by the Company as Exhibit 10.7 to the Company's Registration Statement on Form F-1 (File No. 333-248203), filed with the Securities and Exchange Commission on August 20, 2020.

There is no arrangement or understanding between Mr. Ede-Golightly and any other person pursuant to which Mr. Ede-Golightly was selected as a director of the Company, and there is no family relationship between Mr. Ede-Golightly and any of the Company's other directors or executive officers. Mr. Ede-Golightly does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K.

**Item 7.01 Regulation FD Disclosure.**

On December 15, 2025, the Company issued a press release announcing the executive changes discussed above. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

------

**Item 9.01 Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| [<u>99.1</u>](sln-ex99_1.htm) | [<u>Press Release dated December 15, 2025</u>](sln-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Silence Therapeutics plc | Silence Therapeutics plc |
| Date: December 15, 2025 | By: | /s/ Rhonda Hellums |
|  |  | Name: **Rhonda Hellums** |
|  |  | Title: Chief Financial Officer  |

---

------

## Exhibit 99.1

**Exhibit 99.1**

**Silence Therapeutics Announces Leadership Changes**

15 December 2025

LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025.

Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence Non-Executive Director, has been re-appointed to the Company's Board of Directors. An additional appointment of a US-based Board member is anticipated in due course.

Iain Ross, Chairman of Silence, said: "We thank Craig for his many contributions to Silence and wish him well for the future. The Company is in robust health both financially and operationally and we look forward to further commercial and scientific advancements with our pipeline."

**About Silence Therapeutics**

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company's business strategy and plans, including the Company's anticipated financial and operational health; anticipated changes to the Company's Board of Directors and the Company's ability to bring develop further commercial and scientific advancements with its pipeline. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the Company's history of net operating losses; the Company's ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the Company's product candidates; the Company's ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the Company's product candidates; the Company's reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the Company's ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled "Risk Factors" contained in the

------

Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the Company's other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Inquiries:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Silence Therapeutics plc**<br>Gem Hopkins, VP, IR and Corporate Communications<br>ir@silence-therapeutics.com<br>| &nbsp;&nbsp;Tel: +1 (646) 637-3208<br>|

---

------